

CPT° CODING ALERT

AMA announces CPT update for COVID-19 booster candidates

The American Medical Association (AMA) has announced an editorial update to Current Procedural Terminology (CPT°), the nation's leading medical terminology code set for describing health care procedures and services, that includes newly assigned provisional CPT codes for COVID-19 booster candidates from Pfizer and Sanofi-GlaxoSmithKline.

The Pfizer booster candidate is proposed for use in children ages 5 to 11 who have completed a COVID-19 vaccine primary series, while the Sanofi-GSK booster candidate is proposed for use in persons age 18 and older who have completed a COVID-19 vaccine primary series.

For quick reference, the new product code and administration codes assigned to each COVID-19 booster candidate are:

Product and administration codes for Sanofi-GSK booster candidate

- 91310 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use
- 0104A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose

Administration code for Pfizer booster candidate

0074A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose

LEARN MORE

American Medical Association

Email Preferences | Contact Us

Copyright 2022. American Medical Association. All rights reserved.

American Medical Association. 330 N. Wabash Ave., Suite 39300, Chicago, IL 60611-5885 | (800) 262-3211

To unsubscribe from this email please click here.